China High definition Doxycycline Hyclate 100 M - Nirmatrelvir – CPF manufacturers and suppliers

High definition Doxycycline Hyclate 100 M - Nirmatrelvir – CPF

Short Description:

Product Detail

Product Tags

Feedback (2)

No matter new consumer or outdated shopper, We believe in lengthy expression and trusted relationship for Telaprevir, Apixaban Supplier, Doxycycline Supplier, We have expanded our business into Germany, Turkey, Canada, U. S. A. , Indonesia, India, Nigeria, Brazil and some other regions of the world. We are working hard to be one of the best global suppliers.

High definition Doxycycline Hyclate 100 M - Nirmatrelvir – CPF Detail:

Nirmatrelvir is an inhibitor of the SARS-CoV-2 main protease (Mpro), also referred to as 3C-like protease (3CLpro) or nsp5 protease. Inhibition of SARS-CoV-2 Mpro renders it incapable of processing polyprotein precursors, preventing viral replication.

Nirmatrelvir inhibited the activity of recombinant SARS-CoV-2 Mpro in a biochemical assay at concentrations achievable in vivo. Nirmatrelvir was found to bind directly to the SARS-CoV-2 Mpro active site by X-ray crystallography.

Ritonavir is an HIV-1 protease inhibitor but is not active against SARS-CoV-2 Mpro. Ritonavir inhibits the CYP3A-mediated metabolism of nirmatrelvir, resulting in increased plasma concentrations of nirmatrelvir.

This medication is recommended. It is has been granted an emergency use authorization by FDA for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Nirmatrelvir/ritonavir should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Recommendations are based on EPIC-HR, a Phase2/3 randomized clinical control trial assessing the efficacy of nirmaltrelivir/ritonavir vs. placebo in reduction of hospitalization and or death through day 28. The use of nirmaltrelivir/ritonavir within 5 days of symptom onset in individuals at risk for progression to severe disease reduced the relative risk of hospitalization or death through 28 days by 88%.

2018 GMP-2
原料药GMP证书201811（captopril ,thalidomide etc）
GMP-of-PMDA-in-Chanyoo-平成28年08月03日　Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.

VIEW MORE

VIEW MORE

International cooperation

Domestic cooperation

Product detail pictures:

Related Product Guide:

"Sincerity, Innovation, Rigorousness, and Efficiency" could be the persistent conception of our organization for your long-term to establish alongside one another with shoppers for mutual reciprocity and mutual benefit for High definition Doxycycline Hyclate 100 M - Nirmatrelvir – CPF , The product will supply to all over the world, such as: Casablanca, Armenia, Venezuela, We pursue the management tenet of "Quality is superior, Service is supreme, Reputation is first", and will sincerely create and share success with all clients. We welcome you to contact us for more information and look forward to working with you.

Doxycycline Hyclate 50mg Capsules